| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.95 | 6.23 | 29.93 | 12.91 |
Op profit growth | 5.69 | 31.83 | 43.27 | 2.94 |
EBIT growth | 0.55 | 43.48 | 35 | -2.82 |
Net profit growth | 3.82 | 40.63 | 78.63 | -29.26 |
Profitability ratios (%) | ||||
OPM | 19.3 | 21.91 | 17.65 | 16.01 |
EBIT margin | 17.97 | 21.44 | 15.87 | 15.28 |
Net profit margin | 15.47 | 17.87 | 13.5 | 9.82 |
RoCE | 17.98 | 21.58 | 18.41 | 16.72 |
RoNW | 5.13 | 5.85 | 5.11 | 3.38 |
RoA | 3.87 | 4.49 | 3.91 | 2.68 |
Per share ratios (₹) | ||||
EPS | 140.55 | 135.32 | 96.14 | 53.4 |
Dividend per share | 34 | 30 | 25 | 13 |
Cash EPS | 112.21 | 109.6 | 73.12 | 40.8 |
Book value per share | 722.44 | 616.96 | 515.25 | 406.78 |
Valuation ratios | ||||
P/E | 25.73 | 20.48 | 24.22 | 37.02 |
P/CEPS | 32.23 | 25.29 | 31.84 | 48.44 |
P/B | 5 | 4.49 | 4.51 | 4.86 |
EV/EBIDTA | 19.56 | 15.14 | 17.98 | 21.39 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 24.63 |
Tax payout | -8.81 | -12.17 | -8.76 | -31.05 |
Liquidity ratios | ||||
Debtor days | 59.92 | 67.04 | 59.7 | 50.98 |
Inventory days | 91.26 | 85.04 | 71.32 | 75.25 |
Creditor days | -47.69 | -53.34 | -50.85 | -57.59 |
Leverage ratios | ||||
Interest coverage | -36.5 | -32.26 | -20.36 | -17.73 |
Net debt / equity | 0.01 | -0.02 | 0.08 | 0.08 |
Net debt / op. profit | 0.04 | -0.1 | 0.35 | 0.4 |
Cost breakup (₹) | ||||
Material costs | -39.3 | -39.46 | -40.08 | -39.13 |
Employee costs | -18.45 | -18.28 | -18.04 | -18.55 |
Other costs | -22.92 | -20.33 | -24.21 | -26.29 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
